Recently, “HPV vaccine anxiety” and other topics related to HPV vaccine have frequently appeared on Weibo hot search. Some deputies to the National People’s Congress suggested that school-age women should be vaccinated with domestic HPV vaccine free of charge. Some colleges and universities introduced nine prices for female teachers and students in school. The situation of “one shot is difficult to obtain” of HPV vaccine has aroused many netizens’ discussion.
At present, how about HPV vaccine in China? Which listed companies are involved? The reporter of Beijing business daily learned that at present, there are three HPV vaccine suppliers approved to be listed in China, of which Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) ( Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) ) is the only domestic HPV vaccine supplier. In addition, the HPV vaccine jiadaxiu under MSD is exclusively represented by Chongqing Zhifei Biological Products Co.Ltd(300122) A-share listed company. However, at present, more and more Chinese pharmaceutical enterprises are conducting clinical trials of HPV vaccine. It is believed that people of appropriate age can be more easily vaccinated with HPV vaccine in the future. Among the companies currently conducting clinical trials of HPV vaccine, Kangle guard and Ruike biology are planning to go public.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) is the first domestic HPV vaccine company approved for listing
the bivalent HPV vaccine jointly developed by Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) and Xiamen University is the first domestic HPV vaccine approved for marketing in China, compared with only two HPV vaccine manufacturers in the world.
Data show that human papillomavirus (HPV) vaccine, commonly known as cervical cancer vaccine, can be used to prevent female cervical cancer, male and female genital cancer and genital warts.
According to the official website of the State Drug Administration, in December 2019, the State Drug Administration approved the application for listing and registration of the bivalent human papillomavirus vaccine (E. coli) of Xiamen Wantai Canghai Biotechnology Co., Ltd. (hereinafter referred to as “Wantai Canghai”), which is the first approved domestic HPV vaccine for women aged 9-45.
It is understood that Wantai Canghai is the holding subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) A-share listed company Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) landed on the Shanghai Stock Exchange in 2020. In addition to vaccine R & D, production and sales, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) also engaged in in in vitro diagnostic reagents, automatic testing equipment and other businesses. According to Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) 2021 semi annual report, in the first half of 2021, the company’s new pre potting syringe product line of bivalent HPV vaccine was approved, which increased the company’s comprehensive production capacity of bivalent HPV vaccine to 20 million pieces / year. In addition, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) is also developing a nine valent HPV vaccine and is currently conducting phase III clinical trials.
Benefiting from the company’s continued booming production and marketing of bivalent HPV vaccine, the operating revenue and attributable net profit of Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) 2021 both increased Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) 2021 performance express shows that the company achieved an operating revenue of about 5.75 billion yuan during the reporting period, with a year-on-year increase of 144.25%; The corresponding attributable net profit was about 2.016 billion yuan, a year-on-year increase of 197.83%.
For company related issues, the reporter of Beijing Business Daily called Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) Secretary Office for an interview, but no one answered the phone.
Chongqing Zhifei Biological Products Co.Ltd(300122) exclusive agent of mosadon HPV Vaccine
In addition to the bivalent vaccine produced by Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) production, the bivalent vaccine produced by GlaxoSmithKline in the UK and the tetravalent vaccine and jiuvalent vaccine produced by methadone in the United States have been listed all over the world. Among them, the HPV vaccine jiadaxiu under MSD is exclusively represented by Chongqing Zhifei Biological Products Co.Ltd(300122) A-share listed company.
At present, the nine price vaccine that is very difficult to get on the market is the nine price jiadaxiu represented by Chongqing Zhifei Biological Products Co.Ltd(300122) as mentioned above. Xiao He, who was vaccinated with the nine valent vaccine in October last year, told the Beijing Business Daily that he had planned to vaccinate in Beijing, but Beijing had not been able to make an appointment, so he specially went to Shijiazhuang for the first shot.
Statistics show that Chongqing Zhifei Biological Products Co.Ltd(300122) has been acting as an agent to promote and distribute imported vaccines of MSD in recent years. On November 5, 2018, Chongqing Zhifei Biological Products Co.Ltd(300122) and MSD agreed on the product basic purchase amount of about 18.002 billion yuan from January 1, 2019 to June 30, 2021 for the four and nine valent HPV vaccines; And make unified adjustment and renew the contract at the end of 2020.
The above agency business has contributed a lot to Chongqing Zhifei Biological Products Co.Ltd(300122) and the revenue and attributable net profit of Chongqing Zhifei Biological Products Co.Ltd(300122) have always maintained stable growth in recent years. According to the financial data, from 2018 to 2020, Chongqing Zhifei Biological Products Co.Ltd(300122) achieved operating revenue of about 5.228 billion yuan, 10.59 billion yuan and 15.19 billion yuan respectively; The corresponding attributable net profits are about 1.451 billion yuan, 2.366 billion yuan and 3.301 billion yuan respectively.
Chongqing Zhifei Biological Products Co.Ltd(300122) 2021 performance express shows that the company’s revenue and net profit continue to grow in 2021, and the operating revenue during the reporting period is about 30.637 billion yuan, a year-on-year increase of 101.68%; The corresponding attributable net profit was about 10.197 billion yuan, a year-on-year increase of 208.88%.
Deng Zhidong, general manager of Hainan Boao Medical Technology Co., Ltd., said that at present, China’s four price and nine price HPV vaccines still mainly rely on imports and are monopolized by International Vaccine giants, resulting in market shortage. As a country with a large population base, China is one of the countries with the heaviest burden of cervical cancer. Due to the huge market demand, HPV vaccine can still create huge economic value. In addition, there is a huge international market demand for HPV vaccine. Therefore, the layout of HPV vaccine business not only has high social value, but also can bring economic value to enterprises.
Ruike biology and Kangle guard are preparing for IPO
Although only Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) the bivalent vaccine of domestic HPV vaccine has been approved for listing, many enterprises are developing HPV vaccine, and two enterprises are planning IPO. Among them, Ruike biology is planning to list in Hong Kong stock market, and Kangle guard plans to log on to the Beijing stock exchange.
According to the data disclosed by the National Health Commission in December last year, since 2006, a total of 18 HPV vaccine clinical trials applied for by 9 enterprises in China have been approved. At present, the nine valent vaccines of Kangle guards, Ruike biology, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) and other enterprises have successively started phase III clinical trials in 2021.
Statistics show that on January 21, Ruike biology officially submitted a prospectus to the Hong Kong stock exchange. According to the prospectus, Ruike biology mainly focuses on the research and development of HPV candidate vaccines and operates a business model based on independent research and development of new vaccines. Rec603 is one of the only five HPV nine valent vaccine candidates in phase III clinical trials in China, so it may become the first batch of approved domestic HPV nine valent vaccine products, rec603 said.
On October 14, 2021, the company selected the unqualified stock to be listed in Beijing Securities Regulatory Commission and submitted the materials to Beijing Securities Regulatory Commission. At present, the counseling acceptance has been completed.
According to the annual report of Kangle Weishi in 2021, by the end of 2021, the company’s three valent HPV vaccine and nine valent HPV vaccine (female indications) in research projects have entered phase III clinical practice, and the nine valent HPV vaccine (male indications) in research projects have entered phase I clinical practice.
It is worth mentioning that Ruike biology and Kangle guard are currently at a loss. According to the financial data, the losses of Ruike biology during the period from 2019 to 2020 and the first three quarters of 2021 were 138 million yuan, 179 million yuan and 520 million yuan respectively; The attributable net profit of Kangle guard in 2021 was about – 380 million yuan, with a loss of 152 million yuan in the same period last year.
Song Qinghui, an economist, said in an interview with the Beijing Business Daily that HPV vaccine research and development is difficult, so relevant companies will invest more in research and development, which will affect the company’s profitability to a certain extent. With more and more capital pouring into the HPV vaccine track, the capitalization trend of HPV vaccine companies is obvious and the market growth potential is huge. At the same time, the pace of domestic substitution for import of HPV vaccine will be further accelerated.
